The Food and Drug Administration (FDA) has granted accelerated approval to Tazverik™ (tazemetostat; Epizyme) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.

The approval was based on an open-label, multicenter, phase 2 study (NCT01897571) that assessed the efficacy and safety of tazemetostat 800mg twice daily as monotherapy for adult patients with follicular lymphoma with either EZH2 activating mutations (n=45) or wild-type EZH2 (n=54), who had received at least 2 prior lines of systemic therapy. The primary end point was objective response rate (ORR); secondary end points included progression-free survival (PFS) and safety. 

Findings from the study showed that tazemetostat achieved meaningful clinical activity according to the International Working Group Non-Hodgkin Lymphoma criteria as assessed by an independent review committee. Among patients with EZH2 activating mutations, the ORR was 69% (95% CI, 53-82), of which 12% achieved complete response and 57% achieved partial response. The median duration of response (DoR) and PFS were 10.9 months and 14 months, respectively.

Continue Reading

Additionally, the ORR was 34% (95% CI, 22-48) for patients with wild-type EZH2, of which 4% achieved complete response and 30% achieved partial response. The median DoR and PFS were 13 months and 11 months, respectively. 

With regard to safety, the most common treatment-emergent adverse events included fatigue, upper respiratory tract infection, musculoskeletal pain, nausea and abdominal pain. Serious adverse reactions occurred in 30% of patients who received tazemetostat, most often from infection. 

Related Articles

“The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma,” said John P. Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine, an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center, and an investigator in the Phase 1b/3 confirmatory trial for Tazverik for FL.

The FDA also approved the cobas EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat.

Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The product is supplied as 200mg strength tablets in 240-count bottles.

For more information visit

This article originally appeared on MPR